Top Page
MicroPort Scientific
(OTC:0853)
MicroPort Scientific (0853) vs. iShares MSCI Hong Kong ETF (EWH)
MicroPort Scientific Business Overview & Revenue Model
MicroPort Scientific Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.03B | 950.73M | 840.83M | 778.64M | 648.73M |
| Gross Profit | 574.09M | 532.10M | 501.77M | 491.77M | 436.03M |
| EBITDA | -45.30M | -382.54M | -430.26M | -251.29M | -106.87M |
| Net Income | -214.04M | -477.63M | -436.51M | -351.30M | -223.35M |
Balance Sheet | |||||
| Total Assets | 3.63B | 3.93B | 3.99B | 4.38B | 2.47B |
| Cash, Cash Equivalents and Short-Term Investments | 974.48M | 1.13B | 1.24B | 1.75B | 1.00B |
| Total Debt | 1.69B | 1.70B | 1.47B | 1.24B | 296.31M |
| Total Liabilities | 2.49B | 2.53B | 2.20B | 2.16B | 1.08B |
| Stockholders Equity | 603.47M | 757.82M | 1.14B | 1.49B | 1.13B |
Cash Flow | |||||
| Free Cash Flow | -158.10M | -430.99M | -600.58M | -505.45M | -143.58M |
| Operating Cash Flow | -49.67M | -231.87M | -343.30M | -257.53M | -23.20M |
| Investing Cash Flow | -149.73M | -376.81M | -412.75M | -655.74M | -148.13M |
| Financing Cash Flow | -97.92M | 434.90M | 273.00M | 1.66B | 846.89M |
MicroPort Scientific Technical Analysis
MicroPort Scientific Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$7.53B | 25.24 | 10.92% | 1.07% | 20.19% | 45.54% | |
73 Outperform | HK$8.94B | 37.98 | 6.49% | ― | 0.87% | -18.05% | |
67 Neutral | HK$8.58B | 43.12 | 4.39% | 0.97% | -32.05% | -54.47% | |
66 Neutral | HK$8.79B | 31.58 | 15.22% | 1.26% | 12.48% | 71.75% | |
54 Neutral | HK$21.86B | ― | -160.49% | ― | 141.72% | 38.39% | |
50 Neutral | AU$2.60B | 3.65 | -58.14% | 2.69% | 36.37% | 13.78% | |
46 Neutral | HK$24.25B | ― | -31.45% | ― | 8.11% | 55.55% |
MicroPort Scientific Corporate Events
MicroPort Scientific Corporation has announced the partial conversion of its convertible loans, resulting in the issuance of 43,549,965 new shares. This conversion, valued at approximately US$41.5 million, represents 2.34% of the company’s issued shares prior to the conversion and 2.29% post-conversion. The new shares will carry the same rights as existing shares, including dividend rights, which may impact the company’s equity structure and shareholder value.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$7.30 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific Corporation has announced the proposed disposal of 290,670,408 shares by its substantial shareholder, Otsuka Medical Devices Co., Ltd. The shares are to be acquired by various purchasers, including a fund managed by Shanghai SIIC Capital Management Co., Ltd. The board of MicroPort welcomes SIIC Capital as a strategic shareholder, anticipating that its involvement will support the company’s expansion, strategic mergers and acquisitions, and enhance corporate governance. This move is expected to bolster MicroPort’s core businesses and facilitate its growth and innovation in the healthcare sector.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$7.30 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific Corporation announced a slight revenue decrease of no more than 4% for the first half of 2025, primarily due to geopolitical challenges, domestic competition, and price adjustments influenced by refined medical insurance cost policies. Despite these challenges, the company is optimizing resources and disposing of non-core businesses, but it still anticipates a loss of up to US$110 million for the period, slightly higher than the previous year’s loss.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$7.30 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific Corporation has announced a non-binding proposal for the strategic restructuring of its cardiac rhythm management (CRM) business. The proposal aims to consolidate the CRM business with MicroPort CardioFlow Medtech Corporation to enhance resource integration, competitiveness, and long-term value creation. This restructuring is expected to impact the company’s operations by fostering collaboration between different business segments, although it remains subject to further negotiations, definitive agreements, and necessary approvals.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$7.30 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific Corporation announced that its subsidiary, Shanghai MicroPort Endovascular MedTech Co., Ltd., reported an expected revenue of RMB708.4572 million to RMB787.1747 million for the first half of 2025, indicating a potential decrease compared to the previous year. Despite the decline, the company achieved several R&D breakthroughs and expanded its international market presence, with products now used in over 2,700 hospitals in China and certified in the EU. These developments suggest a strategic focus on innovation and global expansion, which could enhance its competitive positioning in the medical technology sector.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$7.30 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific Corporation has established a Nomination Committee as part of its governance structure, in accordance with the resolution of its Board of Directors. This move is aimed at enhancing the company’s corporate governance practices, potentially impacting its operational efficiency and stakeholder confidence.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$7.30 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific Corporation has announced the appointment of Mr. Jonathan W. Chen as the Rotating Co-chief Executive Officer, effective June 27, 2025. This strategic move is part of the company’s efforts to strengthen its internationalization and professionalization, as well as to develop a young management talent pipeline. Additionally, Dr. Brian Yale Chang has been appointed as the Chief Medical Officer, responsible for overseeing medical affairs strategies and providing expert medical insights across the company’s global operations. These appointments are expected to inject new momentum into MicroPort’s strategic execution and sustainable growth, enhancing its operational capabilities and expanding its global presence.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$7.30 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific Corporation announced that all proposed resolutions at its Annual General Meeting on May 30, 2025, were approved by shareholders. Key resolutions included the re-election of directors, authorization of director remuneration, reappointment of KPMG as auditor, and granting mandates for share buybacks and issuance. This successful AGM reflects strong shareholder support, potentially enhancing the company’s governance and operational strategies.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$7.30 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific’s subsidiary, Shanghai Latent, has entered into a Block Trade Agreement to sell up to 3% of Shanghai MedBot’s issued share capital through placing agents. This transaction, alongside a simultaneous placing agreement by Shanghai MedBot, involves a significant discount on the sale price compared to recent market prices, indicating a strategic move to adjust its financial positioning without creating a new substantial shareholder.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$7.30 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.